Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Anti-cytomegalovirus prophylaxis in solid-organ transplant recipients Falagas ME; Vardakas KZClin Microbiol Infect 2006[Jul]; 12 (7): 603-5Ganciclovir and its prodrug, valganciclovir, are more effective than acyclovir in preventing cytomegalovirus (CMV) infection and disease in solid-organ transplant recipients. However, the indirect effects of prophylactic use of ganciclovir and acyclovir are comparable, and the greater effectiveness of ganciclovir may be compensated for by less drug-related toxicity with acyclovir or valacyclovir. No conclusive data exist concerning the best technique and duration of surveillance for CMV infection in patients for whom active surveillance for late-onset CMV should be performed, i.e., those reaching the end of prophylaxis. Only large randomised controlled trials, with long follow-up periods, will provide definitive conclusions regarding the comparative prophylactic roles of the major antiviral agents in this population, and how their use fits with a strategy of active surveillance and pre-emptive therapy.|*Organ Transplantation[MESH]|Acyclovir/analogs & derivatives/therapeutic use[MESH]|Antiviral Agents/adverse effects/*therapeutic use[MESH]|Cytomegalovirus Infections/*prevention & control[MESH]|Ganciclovir/adverse effects/analogs & derivatives/therapeutic use[MESH]|Humans[MESH]|Valacyclovir[MESH]|Valganciclovir[MESH]|Valine/analogs & derivatives/therapeutic use[MESH] |